| Similar Articles |
|---|
 |
The Motley Fool
April 19, 2005
Nathan Slaughter |
Diagnosis: JNJ A-OK The health-care conglomerate beats expectations on strong international results.   |
The Motley Fool
January 25, 2007
Brian Lawler |
Johnson & Johnson's Earnings Glee Johnson & Johnson keeps growing, even if the pharmaceutical segment is a bit sluggish. Investors, take note. |
The Motley Fool
July 13, 2004
Jeff Hwang |
J&J Weathers Stent Duel The medical device and diagnostics business Johnson & Johnson delivers a solid second quarter despite competition from Boston Scientific's Taxus stent. |
The Motley Fool
October 12, 2004
Alyce Lomax |
Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson? |
The Motley Fool
April 15, 2009
Brian Orelli |
Johnson & Johnson Still Withstands Recession While Johnson & Johnson is big, it has proven to be agile during the recession, and this quarter was no different. |
The Motley Fool
January 26, 2011
Brian Orelli |
J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot. |
The Motley Fool
April 21, 2010
Brian Orelli |
Yawn! Get Back to Me Next Quarter, J&J There's more stagnant growth from the health-care giant. |
The Motley Fool
June 11, 2007
Brian Lawler |
Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul. |
The Motley Fool
October 19, 2011
Brian Orelli |
Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson. |
The Motley Fool
October 13, 2009
Brian Orelli |
J&J Needs to Get Drugged Up Medical devices and diagnostics pass by drugs as the main revenue source. |
The Motley Fool
January 20, 2004
Alyce Lomax |
Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings. |
The Motley Fool
October 14, 2008
Brian Orelli |
Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years. |
The Motley Fool
April 13, 2004
Alyce Lomax |
J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter. |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
October 19, 2010
Brian Orelli |
Watch a 40% Decline Disappear The greatest thing going for Johnson & Johnson is its diversity in product offerings. |
The Motley Fool
January 20, 2009
Brian Orelli |
Johnson & Johnson Nimble ... for Now The health-care giant reports increasing earnings, despite falling revenue. |
The Motley Fool
October 26, 2010
Brian Orelli |
Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs. |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
January 15, 2010
Brian Orelli |
The Odor Lingers at Johnson & Johnson The company has to recall products because of a smelly problem. |
The Motley Fool
November 8, 2011
Brian Wilson |
2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues. |
The Motley Fool
August 27, 2010
Brian Orelli |
A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much. |
The Motley Fool
August 24, 2010
Brian Orelli |
One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well. |
The Motley Fool
July 17, 2007
Ryan Fuhrmann |
Diagnosing J&J's Product Diversity Health-care giant Johnson & Johnson's blues may indicate trouble ahead for competitors. Investors, take note. |
The Motley Fool
May 20, 2011
Andrea Kalvesmaki |
Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings. |
The Motley Fool
November 9, 2006
Shruti Basavaraj |
The Best Blue Chip for 2007: Johnson & Johnson If you're out looking for the best blue chip money can buy, consider Johnson & Johnson. The stock combines strong growth opportunities with stability. It's the ideal stock to build the core of your portfolio. |
The Motley Fool
July 20, 2010
Brian Orelli |
Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant. |
The Motley Fool
July 14, 2009
Brian Orelli |
J&J Eats a Hard Quarter Tough year-over-year comparisons are no match for the health care giant. |
The Motley Fool
May 20, 2009
Brian Orelli |
Johnson & Johnson Tries to Pull a Travolta Johnson & Johnson seems to be making a comeback, after its drug-eluting stent market share fell precipitously to just 15% in the first quarter. |
The Motley Fool
October 12, 2007
Billy Fisher |
Dueling Fools: Johnson & Johnson Bear The bearish opinion on J&J is that it is an impressive company that may have its best days behind it. |
The Motley Fool
September 27, 2010
Brian Orelli |
This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time. |
The Motley Fool
October 17, 2006
Brian Lawler |
See Johnson & Johnson Crawl Earnings growth isn't moving right along because the company has become so big. Investors, take note. |
The Motley Fool
October 17, 2007
Brian Orelli |
J&J Puts Band-Aid on the Quarter Investors, Johnson & Johnson's earnings report reads like a one-hit wonder's second album. It goes from good to bad in the blink of an eye -- or in this case, a paragraph or so. |
The Motley Fool
July 12, 2011
Todd Wenning |
What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors. |
The Motley Fool
April 14, 2008
Brian Orelli |
Teva Gets What It Wants Teva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal. |
The Motley Fool
January 17, 2012
Brian Orelli |
Pharma Focus Is Good For Your Portfolio Build your own portfolio. |
The Motley Fool
February 22, 2010
Brian Orelli |
So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits. |
The Motley Fool
June 15, 2011
Brian Orelli |
Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market. |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
The Motley Fool
July 16, 2008
Brian Orelli |
J&J's Lesson to Investors: Diversify! Johnson & Johnson's second-quarter earnings report gives investors an object lesson of the benefits of the principle of diversification. |
The Motley Fool
October 7, 2010
Anand Chokkavelu |
How Johnson & Johnson Really Makes Money Hint: It's not Tylenol. |
The Motley Fool
September 24, 2010
Anand Chokkavelu |
10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list |
The Motley Fool
October 13, 2008
Brian Orelli |
Foolish Forecast: J&J's Diversity Counts Views you can use to get clues on tomorrow's news |
The Motley Fool
December 31, 2009
Brian Orelli |
The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims. |
The Motley Fool
February 28, 2011
Brian Orelli |
Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo. |
The Motley Fool
September 29, 2011
Brian Orelli |
Joint-Venture Acid Reflux Merck ditches its joint venture with Johnson & Johnson. |
The Motley Fool
May 26, 2010
Brian Orelli |
Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues. |
The Motley Fool
January 22, 2009
Brian Orelli |
Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon. |
The Motley Fool
May 12, 2004
Phil Wohl |
Mylan's Big Break? The maker of generic pimple cream wants to lead the pack. Can it? |
